{
    "clinical_study": {
        "@rank": "159677", 
        "arm_group": {
            "arm_group_label": "Treatment (arsenic trioxide)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive arsenic trioxide IV over 2 hours on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "This pilot clinical trial studies arsenic trioxide in treating patients with basal cell\n      carcinoma. Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to\n      stop the growth of tumor cells, either by killing the cells or by stop them from dividing"
        }, 
        "brief_title": "Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma", 
        "condition": [
            "Basal Cell Carcinoma of the Skin", 
            "Recurrent Skin Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Skin Neoplasms", 
                "Carcinoma, Basal Cell", 
                "Carcinoma, Basosquamous", 
                "Carcinoma, Squamous Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine whether administration of arsenic trioxide (ATO) to patients with basal cell\n      carcinoma is associated with a reduction in Gli messenger ribonucleic acid (mRNA) and\n      protein levels in tumor biopsy samples, when compared to baseline levels.\n\n      SECONDARY OBJECTIVES:\n\n      I. To determine whether there is evidence of tumor size reduction of ATO against basal cell\n      carcinoma in humans.\n\n      OUTLINE:\n\n      Patients receive arsenic trioxide intravenously (IV) over 2 hours on days 1-5. Courses\n      repeat every 28 days in the absence of disease progression or unacceptable toxicity."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with basal cell carcinoma (BCC)\n\n          -  Patients ineligible for curative locoregional treatment and have either progressed\n             on, did not tolerate, unwilling to try or ineligible for investigational smoothened\n             antagonist such as vismodegib (GDC 0449), XL 139 (BMS 833923), IPI- 926, LDE225 and\n             PF-04449913\n\n          -  Life expectancy estimate > 3 months\n\n          -  Performance status Eastern Cooperative Oncology Group (ECOG) 0-2\n\n          -  Absolute neutrophil count >= 1,500/mcL\n\n          -  Platelets >= 100,000/mcL\n\n          -  Total bilirubin within normal institutional limits\n\n          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase\n             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])\n             =< 2.5 x institutional upper limit of normal\n\n          -  Creatinine within normal institutional limits\n\n          -  Corrected QT interval (QTC) by 12 lead electrocardiogram (EKG) < 450 msecs\n\n          -  Serum potassium within normal limits\n\n          -  Magnesium within normal limits\n\n          -  Calcium within normal limits\n\n          -  Include the following: ability to understand and the willingness to sign a written\n             informed consent document\n\n          -  Patients must have evaluable tumor and be potentially eligible for pre and post ATO\n             tumor biopsy\n\n        Exclusion Criteria:\n\n          -  Concurrent use of other Investigational agents is prohibited\n\n          -  Patients with cardiac arrhythmias are excluded\n\n          -  Patients receiving potassium wasting diuretics or amphotericin, while not excluded,\n             must be noted to have theoretically increased arrhythmia risks with ATO\n\n          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, recurrent seizure history or psychiatric illness/social situations that\n             would limit compliance with study requirements\n\n          -  Pregnant women and breastfeeding women are excluded from this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "5", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01791894", 
            "org_study_id": "SKIN0015", 
            "secondary_id": "NCI-2013-00387"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (arsenic trioxide)", 
                "description": "Given IV", 
                "intervention_name": "arsenic trioxide", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Arsenic (III) Oxide", 
                    "Arsenic Sesquioxide", 
                    "Arsenous Acid Anhydride", 
                    "AS2O3", 
                    "Trisenox"
                ]
            }, 
            {
                "arm_group_label": "Treatment (arsenic trioxide)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Arsenic trioxide"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 16, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Stanford", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94305"
                }, 
                "name": "Stanford University"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label, Biomarker Study of Arsenic Trioxide for the Treatment of Patients With Basal Cell Carcinoma", 
        "overall_official": {
            "affiliation": "Stanford University", 
            "last_name": "Jean Tang", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Analyzed using nonparametric methods (Wilcoxon sign rank test).", 
            "measure": "Percent decrease in GLI2 protein levels", 
            "safety_issue": "No", 
            "time_frame": "From baseline to day 5 of course 2"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01791894"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Analyzed using Wilcoxon sign rank test.", 
                "measure": "Change in tumor GLI1 protein or mRNA levels", 
                "safety_issue": "No", 
                "time_frame": "From baseline to day 5 of course 2"
            }, 
            {
                "description": "Analyzed using Wilcoxon sign rank test.", 
                "measure": "Tumor size change in the longest diameter, assessed by Response Evaluation Criteria in Solid Tumors (RECIST)", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 1 year"
            }, 
            {
                "measure": "Proportion of subjects with complete response, partial response, stable disease, or disease progression by RECIST criteria", 
                "safety_issue": "No", 
                "time_frame": "At 3 months"
            }, 
            {
                "description": "Adverse events (AEs) attributable to arsenic trioxide will be collected and tabulated for cumulative evaluation.", 
                "measure": "Incidence of adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 3.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 1 year"
            }
        ], 
        "source": "Stanford University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Stanford University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}